Wright Medical Group, Inc. Appoints Pascal E.R. Girin as Executive Vice President and Chief Operating Officer

  Wright Medical Group, Inc. Appoints Pascal E.R. Girin as Executive Vice
  President and Chief Operating Officer

             Company also Announces New U.S. Divisional Structure

   Eric Stookey Promoted to President of Extremities Division and Ted Davis
                 Promoted to President of OrthoRecon Division

Business Wire

ARLINGTON, Tenn. -- November 06, 2012

Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that Pascal E.R.
Girin has been appointed Executive Vice President and Chief Operating Officer.
In this newly created position, Mr. Girin will have global operating
responsibility for Wright's Extremities, OrthoRecon and International
businesses and Clinical, Regulatory and Quality, reporting directly to the
Chief Executive Officer. Mr. Girin’s first day of employment will be the later
of November 19, 2012 or the date the transfer of his visa is finalized.

“I'm delighted to announce Pascal’s appointment to this new position to lead
our global businesses,” stated Robert Palmisano, President and Chief Executive
Officer of Wright Medical. “Pascal is a proven leader with significant
operational experience. While working with me at ev3, Pascal was a major
contributor to the company’s growth and success, including the rapid expansion
of ev3’s worldwide neurovascular business to the #2 overall revenue share
position, the successful acquisition of Chestnut Medical, and the growth of
ev3’s peripheral vascular and international businesses at rates that
significantly outpaced the market.”

Palmisano continued, “In addition to Pascal’s appointment, we have made some
important changes to the way our business is organized and structured. In the
U.S., we will now have an Extremities division and an OrthoRecon division. In
conjunction with this new structure, I’m pleased to announce the promotion of
Eric Stookey to be the President of the Extremities division and Ted Davis to
be the President of the OrthoRecon division. Both Eric and Ted will report to
Pascal Girin in his newly created role of Executive Vice President and Chief
Operating Officer. During their tenure with Wright, both Eric and Ted have
demonstrated their knowledge of our markets, their understanding of our
customers and their leadership within the company. I’m confident that Pascal’s
appointment, as well as our new structure, will further bolster our ability to
capitalize on the growth opportunities in front of us and accelerate our
market performance.”

Prior to joining Wright Medical, Mr. Girin served as Chief Executive Officer
of Keystone Dental Inc. from February 2011 to June 2012 and Executive Vice
President and Chief Operating Officer of Keystone Dental Inc. from October
2010 to February 2011. Prior to Keystone, Mr. Girin served in several
executive roles at ev3 Inc. from September 2003 to September 2010, including
Executive Vice President and Chief Operating Officer; Executive Vice President
and President, Worldwide Neurovascular and International; Senior Vice
President and President, International; and General Manager, Europe. From
September 1998 to August 2003, Mr. Girin served in various capacities at
BioScience Europe Baxter Healthcare Corporation. Mr. Girin received an
engineering education at the French Ecole des Mines. Mr. Girin previously
served on the board of directors of Tornier N.V. from November 2010 to
November 2012.

Wright Medical also announced today that in connection with Mr. Girin’s
appointment as Executive Vice President, Chief Operating Officer and as an
inducement to his employment with Wright, the Compensation Committee of its
Board of Directors approved the grant of a stock option to Mr. Girin, which
will be made on his initial date of employment, to purchase up to 184,500
shares of Wright’s common stock, priced at fair market value as of the grant
date. The stock option vests and becomes exercisable in four equal, annual
installments beginning on the first anniversary of the grant, conditioned on
Mr. Girin’s continued employment. The stock option has a ten year term and is
subject to the terms and conditions of the stock option agreement pursuant to
which the option was granted.

This press release is being made in accordance with NASDAQ Listing Rule

About Wright Medical

Wright Medical Group, Inc. is a global orthopaedic medical device company and
a leading provider of surgical solutions for the foot and ankle market. The
Company specializes in the design, manufacture and marketing of devices and
biologic products for extremity, hip and knee repair and reconstruction. The
Company has been in business for more than 60 years and markets its products
in over 60 countries worldwide. For more information about Wright Medical,
visit the Company’s website at www.wmt.com.


This press release may contain “forward-looking statements” as defined under
U.S. federal securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and express
management's current view of future performance, results, and trends.
Forward-looking statements may be identified by their use of terms such as
anticipate, believe, could, estimate, expect, intend, may, plan, predict,
project, will, and other similar terms. Forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results to
materially differ from those described in the forward-looking statements. The
reader should not place undue reliance on forward-looking statements. Such
statements are made as of the date of this press release, and we undertake no
obligation to update such statements after this date. Risks and uncertainties
that could cause our actual results to materially differ from those described
in forward-looking statements are discussed in our filings with the Securities
and Exchange Commission (including those described in Item 1A of our Annual
Report on Form 10-K for the year ended December 31, 2011 and our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012, in each case
under the heading “Risk Factors” and elsewhere in such filings). By way of
example and without implied limitation, such risks and uncertainties include:
future actions of the United States Attorney’s office, the FDA, the Department
of Health and Human Services or other U.S. or foreign government authorities
that could delay, limit or suspend our development, manufacturing,
commercialization and sale of products, or result in seizures, injunctions,
monetary sanctions or criminal or civil liabilities; any actual or alleged
breach of the Corporate Integrity Agreement to which we are subject through
September 2015 which could expose us to significant liability including
exclusion from Medicare, Medicaid and other federal healthcare programs,
potential criminal prosecution, and civil and criminal fines or penalties;
adverse outcomes in existing product liability litigation; new product
liability claims; inadequate insurance coverage; the possibility of private
securities litigation or shareholder derivative suits; demand for and market
acceptance of our new and existing products; potentially burdensome tax
measures; lack of suitable business development opportunities; product quality
or patient safety issues; challenges to our intellectual property rights;
geographic and product mix impact on our sales; our inability to retain key
sales representatives, independent distributors and other personnel or to
attract new talent; inventory reductions or fluctuations in buying patterns by
wholesalers or distributors; inability to realize the anticipated benefits of
restructuring initiatives; negative impact of the commercial and credit
environment on us, our customers and our suppliers; and the potentially
negative effect of our ongoing compliance enhancements on our relationships
with customers, and on our ability to deliver timely and effective medical
education, clinical studies, and new products.


Wright Medical Group, Inc.
Julie D. Tracy, 901-290-5817
Sr. Vice President, Chief Communications Officer
Press spacebar to pause and continue. Press esc to stop.